Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ).
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced new subscriptions for wealth management products with Industrial Bank and CMB, each amounting to RMB200 million. These transactions, which exceed 5% of the applicable percentage ratio under the Listing Rules, are considered discloseable and subject to reporting and announcement requirements, indicating a strategic financial maneuver to manage its assets and potentially enhance its financial stability.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical sector. The company focuses on developing and managing wealth management products, as evidenced by its recent financial activities.
Average Trading Volume: 806,913
Technical Sentiment Signal: Buy
Current Market Cap: HK$90.43B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.